Satomoto Kensuke, Aoki Moeko, Wakita Atsushi, Yamagata Hiroshi, Mitsumoto Tatsuya, Okamoto Takezo, Harada Ryoko, Hamada Shuichi
BoZo Research Center Inc., 1284 Kamado, Gotemba-shi, Shizuoka 412-0039, Japan.
BoZo Research Center Inc., 1284 Kamado, Gotemba-shi, Shizuoka 412-0039, Japan.
Mutat Res Genet Toxicol Environ Mutagen. 2023 Aug-Sep;890:503658. doi: 10.1016/j.mrgentox.2023.503658. Epub 2023 Jul 10.
The repeated-dose liver micronucleus (RDLMN) assay is a widely accepted method for detecting genotoxic substances. We investigated the effect of animal age on this assay. Proliferation activity in the liver tissue of untreated rats at age = 3.5, 6, 8, 10, or 12 weeks was measured via immunohistochemical expression of Ki-67 protein. The percentage of Ki-67-positive hepatocytes decreased markedly with age, reaching very low levels after 10 weeks, indicating decline with age of proliferative capacities in the liver. We calculated the area under the curve (AUC) of the approximate curve generated from the percentage of Ki-67-positive cells, to estimate the hepatocyte proliferation activity over the dosing period in the two regimens of the 4-week RDLMN assay: dosing initiated at age = 6 or 8 weeks. Hepatocyte proliferation activity of the former regimen was approximately double that of the latter. We also calculated the AUC for the juvenile-rat method, in which rats are treated for two days at age = 3.5 weeks. The AUC calculated for that method was approximately half of that for the 4-week repeated-dosing regimen initiated at 6 weeks of age. These findings suggest that the 4-week RDLMN assay with dosing initiated at age = 6 weeks could be approximately twice as sensitive as the other two methods.
重复剂量肝脏微核(RDLMN)试验是一种广泛认可的检测遗传毒性物质的方法。我们研究了动物年龄对该试验的影响。通过Ki-67蛋白的免疫组化表达来测定3.5、6、8、10或12周龄未处理大鼠肝脏组织中的增殖活性。Ki-67阳性肝细胞的百分比随年龄显著下降,10周后降至极低水平,表明肝脏增殖能力随年龄下降。我们计算了由Ki-67阳性细胞百分比生成的近似曲线的曲线下面积(AUC),以估计4周RDLMN试验两种给药方案给药期间的肝细胞增殖活性:给药起始年龄为6周或8周。前一种给药方案的肝细胞增殖活性约为后一种的两倍。我们还计算了幼鼠法的AUC,即在3.5周龄时对大鼠进行两天的处理。该方法计算出的AUC约为6周龄开始的4周重复给药方案的一半。这些发现表明,6周龄开始给药的4周RDLMN试验的敏感性可能是其他两种方法的两倍左右。